This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Together, the tools estimate how a drug may impact diverse outcomes of interest to drugdevelopers: general cellular health, pharmacokinetics, and heart and liver function. Drugdevelopers also assess pharmacokinetic effects, or how an organism absorbs, distributes, metabolizes, and clears a drug.
As we continue to evolve our drug characterisation processes at Verseon, we see the extensive use of assembloids as essential enabling technology for the future of all drugdevelopment. He received his BS in physics and biology from the University of Chicago and his PhD in molecularbiology from the University of Pennsylvania.
I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecularbiology. It was then that I knew I wanted to dedicate my career to science. Biochemistry and molecularbiology fascinated me in school. BECOME A ROLE MODEL!
This method was more about serendipity than science. But as molecularbiology has advanced, so too has our approach to finding new drugs. Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drugdevelopment for decades.
We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drugdevelopment process which promises to completely transform how we developdrugs with increases in productivity of an order of magnitude or more. One final parallel to 2001.
5 Organoids are recognised as New Alternative Methods (NAMs) in drugdevelopment. This recognition was codified by the United States Food and Drug Administration (FDA) in 2022 with the signing of the FDA Modernisation Act 2.0 This can aid in the development of safer, more effective therapeutic strategies.
Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research.
Transposon technologies are gaining traction due to their accuracy in integrating the gene of interest into the host genome, making them an important tool for accelerating large molecule drugdevelopment. Anis works within the strategy group in Life Sciences at Revvity, Inc. Disclaimer: For research use only.
Caris Life Sciences® (Caris) has been at the forefront of precision medicine. How does the company see antibody-drug conjugates (ADCs) fitting into this approach? However, biopharma pipelines have been focused on optimising linkers and payloads around a relatively small number of cell-surface targets.
via Wikimedia Commons My fellow Altascientists and I recently attended the 2024 annual Boston Society Gene & Cell Therapy Conference , held at the wonderful Museum of Science in, of course, Boston, MA. Connect with Dr. Turcotte on LinkedIn. Image Thumbnail_Blog_June 2024.jpg
(“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. Südhof, M.D.,
. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecularbiology, Penn State. 25) in the journal Communications Biology.
My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. During this time, I had the opportunity to step in as an interim Discovery Sciences project lead, sparking my interest in project leadership.
From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drugdevelopment research for Neurocrine Biosciences, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc.
Internships at Altasciences: Q&A With Our Summer Interns nbartlett Thu, 08/22/2024 - 04:44 Internships at Altasciences are more than just a stepping stone—they’re a gateway to real-world-experience and professional growth, giving the next generation opportunities to help shape progress in the drugdevelopment industry.
At Johnson & Johnson, our differentiated Alzheimer’s disease research program is focused on leveraging the latest advancements in precision medicine, data science and digital health to help make earlier diagnosis an option and help treat the right patient with the right treatment at the right time. link] Cummings J. Adv Exp Med Biol.
Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drugdevelopment and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. of total revenue).
doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.
Barber is an associate professor of biology and director of the Office of Student Research. Dr. Barber is in her tenth year at Longwood and serves as the President-Elect of the Virginia Academy of Science. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.”
With a background in molecularbiology and clinical chemistry, Dr. Zetterberg has spent the last 20 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. He is responsible for launching the professional interest area tied to immunity.
Advances in molecularbiology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. 2023 May 12; Available from: [link] National Academies of Sciences, Engineering, and Medicine.
His areas of expertise include biologic drugdevelopment, cell and gene therapies, and gene editing. Cedrone holds a PhD in molecularbiology and enzyme engineering from Marseille University, France.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content